#ASCO25 MIDAS Trial: After Isa-KRD x 6 cycles in TE NDMM, in MRD -ve (10e-5) pts, no diff. in MRD -ve at 10e-6 in autoSCT vs. IsaKRD consolidation. Longer f/u needed for sustained MRD and PFS #mmsm #bmtsm Aurore Perrot Now in NEJM nejm.org/doi/full/10.10…

A thoughtful and nuanced discussion on the results of MIDAS trial #mmsm #bmtsm Raj Chakraborty Eddie Cliff Meera Mohan podcasts.apple.com/us/podcast/blo…

Talquetamab bridging allows rapid disease control with minimal grade toxicity, enabling treatment with BCMA CAR-T in heavily pretreated, HRMM #mmsm #bmtsm Binod Dhakal Surbhi Sidana, MD Blood Journals Portfolio ashpublications.org/blood/article-…

Opening the Door to Tailored Treatment in Newly Diagnosed Multiple Myeloma | New England Journal of Medicine NEJM Nikhil C. Munshi, MD #mmsm #bmtsm nejm.org/doi/10.1056/NE…

Compared to teclistamab and talquetamab, both Ide-cel and cilta-cel were associated with higher response rates, deeper responses, and longer PFS in RRMM with EMD #mmsm #bmtsm Maximilian Steinhardt Leo Rasche Blood Cancer Journal nature.com/articles/s4140…

Elranatamab elicits deep and rapid heme responses in patients with RR AL amyloidosis without any new AEs, even in patients with advanced heart failure #mmsm #amyloid Raj Chakraborty Bianchi Lab Blood Journals Portfolio Suzanne Lentzsch, MD, PhD ashpublications.org/blood/article-…

Thanks Muzaffar Qazilbash ! We are excited to make this highly effective treatment option available to AL amyloidosis patients through a prospective clinical trial Dana-Farber, shortly opening at other centers in the US. #amyloidosis

Outcomes of patients with NDMM with del (1p) following autoHCT. Median PFS 30.2 months, median OS NR; concomitant del(17p) had worse OS #mmsm #bmtsm Curtis Marcoux MD Anderson Cancer Center astctjournal.org/article/S2666-…

#DavaHeme kicks off at Hamilton Princess with an overview of MM. ⁦Sagar Lonial MD⁩ ⁦Penn Medicine - Abramson Cancer Center⁩ ⁦Robert Z. Orlowski⁩

Starting Now: Allo HSCT, Cellular Therapy, and BiTEs for AML and MDS/MPN Moderated by: Muzaffar Qazilbash MD Anderson Cancer Center #DAVAHeme

Samir Parekh, MBBS, and colleagues successfully treated rare T-cell lymphoma that developed after CAR T-cell therapy for #MultipleMyeloma. mountsinai.org/about/newsroom… Lipschultz Precision Immunology Institute Icahn School of Medicine at Mount Sinai Brown Lab Joshua Brody, MD Miriam Merad, MD, PhD Oliver Van Oekelen Patrick Brunner, MD, MSc Alessandro Lagana'

Excited as co-first author to share our NEJM case report: we describe the successful personalized treatment of a CAR⁺ T-cell lymphoma that developed after anti-BCMA CAR T therapy for multiple myeloma. A remarkable example of precision medicine in action. #mmsm #MultipleMyeloma

Fatal recurrence of IEC-HS after autologous stem cell boost in patients receiving BCMA-CAR T-cell therapy ow.ly/46HM50WEPjH #immunobiologyandimmunotherapy #plasmacelldisorders

Excited to share our new manuscript, now published in Blood! BCMA #CART show impressive responses for #myeloma, but pts with high-risk cytogenetics relapse more quickly and are in urgent need of new therapies. Thread👇 (1/10) ashpublications.org/blood/article/…

Our multicenter series shows bispecific antibodies may offer meaningful CNS activity with manageable safety. Led by fellow Alex N! Meera Mohan Samer Al Hadidi, MD,MS,FACP doi.org/10.1111/bjh.70… #CNSMyeloma #mmsm Rutgers Cancer Institute RWJBarnabas

👉👉👉Fabulous work by Aditi Pemmaraju 📣.Aditi Pemmaraju, J.D. ➡️ Real Estate 🏡 focused on Physicians & Health Professionals & the entire process of Physician Relocation | 🙌 homesforhealers.net compass.com/agents/aditi-p… Ruben A. Mesa, MD Anirban Maitra Sanam Loghavi, MD صنم لغوی 🔬🧬 Muzaffar Qazilbash

Test Cricket: A History. By Tim Wigmore Tim Wigmore Pure joy for lovers of Test cricket! economist.com/culture/2025/0…

CD38 mAb-containing induction is associated with inferior PBSC mobilization yields, more apheresis sessions, and plerixafor use in NDMM #bmtsm #mmsm Lekha Mikkilineni Surbhi Sidana, MD sciencedirect.com/science/articl…

Ide-cel and Cilta-cel for PCL. N=34, median PFS/OS with ide-cel: 6/9 months; median PFS/OS with cilta cel: 19/>23 months #bmtsm #mmsm @GliceidaGalarzaMD Blood Journals Portfolio ashpublications.org/bloodadvances/…

Talquetamab had the lowest rate grade 3/4 infections and discontinuations and deaths due to infections among T-cell engaging antibodies in RRMM (MonumenTAL-1 trial) #mmsm Blood Journals Portfolio Ajai Chari ashpublications.org/bloodadvances/…